INOVIO PHARMACEUTICALS, INC. 8-K

What Happened

• Inovio Pharmaceuticals, Inc. announced an amendment dated January 27, 2026 that extends the expiration of each outstanding Series A Warrant (issued July 7, 2025) to 5:00 p.m. New York City time on March 31, 2026. The warrants would otherwise have expired at 5:00 p.m. on January 28, 2026 (30 days after the company’s public announcement that the FDA accepted the Biologic License Application for INO-3107). All other terms of the warrants remain unchanged. The form of the amendment is filed as Exhibit 4.1 to the 8-K.

Key Details

• Outstanding Series A Warrants cover the right to purchase up to 13,564,268 shares of common stock (or, in lieu of shares, pre-funded warrants, each representing the right to purchase one share at an exercise price of $0.001).
• Exercise price stated as $1.75 per share (or $1.749 per Pre-Funded Warrant) under the Series A Warrants.
• Original expiration: January 28, 2026; New expiration: March 31, 2026 at 5:00 p.m. NYC time.
• A prospectus supplement amendment relating to the extension will be filed with the SEC.

Why It Matters

• The extension gives warrant holders an additional two months to decide whether to exercise, preserving potential dilution risk for common shareholders through March 31, 2026.
• If all warrants were exercised for shares at $1.75, it could represent up to roughly $23.7 million in gross proceeds to the company (actual proceeds depend on mix of share vs. pre-funded-warrant exercises).
• The amendment was tied to the company’s recent regulatory milestone (FDA acceptance of the BLA for INO-3107), which originally set the warrants’ shorter expiration timing; investors should note both the extended exercise window and the connection to INO-3107’s regulatory progress.